Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
donepezil + lithium
- Development stage
- Phase 4
- Lead developer
- Eisai
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of donepezil, an acetylcholinesterase inhibitor, and lithium, a mood stabilizer. This combination has been studied as a potential adjunctive treatment for bipolar disorder, particularly for acute mania. Clinical trials have shown mixed results, with some suggesting short-term benefits but limited long-term efficacy.
02
Targets
AcetylcholinesteraseGSK3 (Glycogen synthase kinase 3 beta)
Beyond the preview
Go deeper on donepezil + lithium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on donepezil + lithium.